Dr. Langer on Practice-Changing PACIFIC Data in Stage III NSCLC

Video

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non—small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

The stage III NSCLC landscape has evolved over the last 1.5 years, said Langer. The standard, he says, until 2017 was standard concurrent radiation. Research efforts to improve outcomes included either increasing radiation dose, adding chemotherapy after chemoradiation, and introducing other targeted agents such as cetuximab (Erbitux) failed and showed no survival increment.

The therapeutic landscape has completely transformed with the game-changing results of the PACIFIC trial, said Langer. The phase III study specifically evaluated the role of durvalumab following standard chemoradiation versus placebo following chemoradiation in a 2:1 randomization showing an absolutely unprecedented improvement in progression-free survival (PFS). Median PFS was short of 5.6 months compared with 16.8 months in the durvalumab arm. There was also no significant increase in toxicity, said Langer, aside from rates of pneumonitis that were manageable. There was also a reduction in the incidence of metastases, he concludes.

The FDA approved durvalumab for the treatment of patients with locally advanced, unresectable stage III NSCLC who have not progressed following chemoradiotherapy in February 2018.

<<< 2018 International Lung Cancer Congress

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania